ABIVAX Société Anonyme

LSE:0RA9 Stock Report

Market Cap: €516.4m

ABIVAX Société Anonyme Valuation

Is 0RA9 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RA9 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0RA9's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0RA9's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RA9?

Key metric: As 0RA9 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0RA9. This is calculated by dividing 0RA9's market cap by their current book value.
What is 0RA9's PB Ratio?
PB Ratio4.1x
Book€126.47m
Market Cap€516.39m

Price to Book Ratio vs Peers

How does 0RA9's PB Ratio compare to its peers?

The above table shows the PB ratio for 0RA9 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average7.2x
AVCT Avacta Group
3.8x-2.1%UK£182.9m
OXB Oxford Biomedica
6.7x93.2%UK£447.3m
BVXP Bioventix
16.3xn/aUK£195.7m
GNS Genus
2x37.7%UK£1.1b
0RA9 ABIVAX Société Anonyme
4.1x2.4%€516.4m

Price-To-Book vs Peers: 0RA9 is good value based on its Price-To-Book Ratio (4.1x) compared to the peer average (7.2x).

Price to Book Ratio vs Industry

How does 0RA9's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.46m
VAL ValiRx
0.6xn/aUS$2.78m
No more companies available in this PB range
0RA9 4.1xIndustry Avg. 2.9xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0RA9 is expensive based on its Price-To-Book Ratio (4.1x) compared to the UK Biotechs industry average (2.9x).

Price to Book Ratio vs Fair Ratio

What is 0RA9's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RA9 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0RA9's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RA9 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€8.51
€29.18
+242.8%
34.7%€45.00€17.70n/a4
Nov ’25€9.60
€29.18
+203.9%
34.7%€45.00€17.70n/a4
Oct ’25€10.08
€29.18
+189.4%
34.7%€45.00€17.70n/a4
Sep ’25€11.44
€36.34
+217.7%
46.6%€65.00€17.70n/a5
Aug ’25€11.20
€36.34
+224.4%
46.6%€65.00€17.70n/a5
Jul ’25€11.66
€35.74
+206.5%
48.7%€65.00€17.70n/a5
Jun ’25€12.30
€35.74
+190.6%
48.7%€65.00€17.70n/a5
May ’25€14.76
€35.74
+142.1%
48.7%€65.00€17.70n/a5
Apr ’25€13.40
€35.60
+165.7%
49.3%€65.00€17.00n/a5
Mar ’25€12.92
€35.60
+175.5%
49.3%€65.00€17.00n/a5
Feb ’25€12.09
€35.60
+194.3%
49.3%€65.00€17.00n/a5
Jan ’25€9.82
€28.25
+187.7%
38.1%€45.00€17.00n/a4
Dec ’24€9.45
€35.20
+272.5%
48.0%€63.00€17.00n/a5
Nov ’24€9.06
€34.20
+277.5%
50.7%€63.00€17.00€9.605
Oct ’24€15.04
€36.00
+139.4%
45.3%€63.00€17.00€10.085
Sep ’24€17.42
€36.00
+106.7%
45.3%€63.00€17.00€11.445
Aug ’24€17.38
€36.00
+107.2%
45.3%€63.00€17.00€11.205
Jul ’24€15.49
€36.00
+132.4%
45.3%€63.00€17.00€11.665
Jun ’24€18.41
€33.70
+83.0%
52.8%€63.00€15.50€12.305
May ’24€15.10
€33.70
+123.2%
52.8%€63.00€15.50€14.765
Apr ’24€7.05
€26.00
+268.8%
44.8%€45.00€14.00€13.404
Mar ’24€6.58
€48.00
+629.5%
49.6%€81.00€14.00€12.924
Feb ’24€7.02
€49.30
+602.3%
44.6%€81.00€19.20€12.094
Jan ’24€6.26
€49.30
+687.5%
44.6%€81.00€19.20€9.824
Dec ’23€7.26
€49.30
+579.1%
44.6%€81.00€19.20€9.454
Nov ’23€7.67
€49.30
+542.9%
44.6%€81.00€19.20€9.064

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Formycon

€848.4m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.50

7D

4.3%

1Y

-21.3%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€63.05

7D

1.3%

1Y

13.6%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$745.13

7D

-2.1%

1Y

-6.5%